Table 3.
Low soluble ICAM-1 and normal CEA concentrations are associated with improved survival in human colorectal carcinoma (n = 297)
| n | 5-year overall survival (%)/95% CI | p value | 5-year cancer-related survival (%)/95% CI | p value | ||
|---|---|---|---|---|---|---|
| sICAM-1low (< 290 ng/ml) | 208 | 75.2/69.3–81.1 | 83.4/78.1–88.7 | |||
| sICAM-1high (≥ 290 ng/ml) | 89 | 52.5/42.1–62.9 | 0.000023 | 66.2/55.6–76.8 | 0.0000144 | |
| CEA normal (< 5 ng/ml) | 199 | 82.3/77.0–87.6 | 90.8/86.7–94.9 | |||
| CEA elevated (≥ 5 ng/ml) | 98 | 40.5/30.7–50.3 | 4.123E−10 | 52.1/41.3–61.9 | 5.135E−14 | |
| UICC stages | ||||||
| Stage I + II | sICAM-1low | 135 | 85.0/78.9–91.1 | 94.2/90.1–98.3 | ||
| sICAM-1high | 37 | 72.6/58.1–87.1 | 0.097 | 96.2/85.6–100 | 0.861 | |
| Stage III | sICAM-1low | 40 | 82.1/10.1–94.1 | 94.2/86.4–100 | ||
| sICAM-1high | 23 | 64.7/44.9–84.5 | 0.048 | 84.1/67.6–100 | 0.114 | |
| Stage IV | sICAM-1low | 33 | 27.3/12.0–42.6 | 28.2/12.5–43.9 | ||
| sICAM-1high | 29 | 17.2/3.5–30.9 | 0.257 | 19.2/4.5–33.9 | 0.265 | |
| Stage I + II | CEA normal | 136 | 88.2/82.7–93.7 | 96.0/92.5–99.5 | ||
| CEA elevated | 36 | 60.4/44.1–76.7 | 0.009 | 87.9/75.0–100 | 0.107 | |
| Stage III | CEA normal | 47 | 78.1/66.1–90.1 | 92.3/83.9–100 | ||
| CEA elevated | 16 | 68.8/46.1–91.5 | 0.990 | 86.5/69.1–100 | 0.657 | |
| Stage IV | CEA normal | 16 | 43.8/19.5–68.1 | 43.8/19.5–68.1 | ||
| CEA elevated | 46 | 15.2/4.8–25.6 | 0.082 | 16.5/5.3–27.7 | 0.111 | |
sICAM-1 soluble intercellular adhesion molecule-1, CEA carcinoembryonic antigen, UICC Union Internationale Contre le Cancer
All R classifications are included in the survival analysis